Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, covers how MS patients on Mavenclad are less likely to experience a disease relapse than those on other oral DMTs like Gilenya, Tecfidera, or Aubagio. He also reads “The Double-Edged Sword of Fatigue Medications”, from Beth Ullah's column "Through the Looking Glass". =================================== Are you interested in learning more about multiple sclerosis? If so, please visit:

https://multiplesclerosisnewstoday.com/

===================================== To join in on conversations regarding multiple sclerosis, please visit:

https://multiplesclerosisnewstoday.com/forums/